Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Phys Condens Matter ; 34(41)2022 Aug 04.
Artigo em Inglês | MEDLINE | ID: mdl-35896108

RESUMO

A proposal for simulating the Dicke-Lattice model in a mechanics-controlled hybrid quantum system is studied here. An array of coupled mechanical resonators (MRs) can homogeneously interact with a group of trapped Bose-Einstein condensates (BECs) via the gradient magnetic field induced by the oscillating resonators. Assisted by the classical dichromatic radio-wave fields, each subsystem with the BEC-MR interaction can mimic the Dicke type spin-phonon interaction, and the whole system is therefore extended to a lattice of Dicke models with the additional adjacent phonon-phonon hopping couplings. In view of this lattice model with theZ2symmetry, its quantum phase transitions behavior can be controlled by this periodic phonon-phonon interactions in the momentum space. This investigation may be considered as a fresh attempt on manipulating the critical behaviors of the collective spins through the external mechanical method.

2.
Immunotherapy ; 11(17): 1481-1490, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31713453

RESUMO

Aim: We performed a meta-analysis to explore the efficacy of immunotherapy for patients with squamous non-small-cell lung cancer (NSCLC). Materials & methods: Randomized clinical trials comparing immunotherapy with chemotherapy for advanced NSCLC patients were included. Results: A total of 11 trials (3112 patients) were included. PD-1/PD-L1 inhibitors demonstrated significant superiority to chemotherapy in overall survival (OS) (hazard ratio [HR]: 0.74; p < 0.001) and progression-free survival (PFS) (HR: 0.66; p < 0.001) for squamous NSCLC. The OS and PFS benefits of PD-1/PD-L1 inhibitors for squamous NSCLC were similar in subgroup analyses of line settings, PD-L1 expression and different study methodologies. No advantage in OS was found in advanced squamous NSCLC patients treated with atezolizumab (HR: 0.87; p = 0.087). Conclusion: PD-1/PD-L1 inhibitors significantly improved OS and PFS in advanced squamous NSCLC patients when compared with chemotherapy.


Assuntos
Antígeno B7-H1/antagonistas & inibidores , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias de Células Escamosas/tratamento farmacológico , Receptor de Morte Celular Programada 1/antagonistas & inibidores , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Humanos , Neoplasias Pulmonares/mortalidade , Neoplasias de Células Escamosas/mortalidade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa